A GSK-Structural Genomics Consortium team has identified the first potent and selective histone demethylase inhibitor and shown that the molecule dampens the macrophage inflammatory response. The pharma now is focusing on internal efforts and external approaches to exploring potential therapeutic applications of the inhibitor.